Coeptis Therapeutics Holdings, Inc. (COEP) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Coeptis Therapeutics Holdings, Inc. (COEP:NASDAQ), powered by AI.

Current Price
$16.40
P/E Ratio
-3.2
Market Cap
32M
Sector
Healthcare
What is the Coeptis Therapeutics Holdings, Inc. stock price forecast?

Coeptis Therapeutics Holdings, Inc. is currently trading at $16.40. View real-time AI analysis on Alpha Lenz.

What is Coeptis Therapeutics Holdings, Inc. insider trading activity?

View the latest insider trading data for Coeptis Therapeutics Holdings, Inc. on Alpha Lenz.

What is Coeptis Therapeutics Holdings, Inc.'s P/E ratio?

Coeptis Therapeutics Holdings, Inc.'s P/E ratio is -3.2.

Coeptis Therapeutics Holdings, Inc.

NASDAQ · COEP
$16.40
Ask about Coeptis Therapeutics Holdings, Inc.'s future dividend policy...
Alpha Chat Insight

Coeptis Therapeutics Holdings, Inc. trades at a P/E of -3.2 (undervalued) with modest ROE of -490.8%.

Ask for details

Company Overview

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company that concentrates on developing cell therapy technologies for the treatment of cancer. At the forefront of innovative medical solutions, Coeptis focuses on enhancing the effectiveness of existing oncology therapies, aiming to improve outcomes for patients battling various forms of cancer. One of the defining features of Coeptis Therapeutics is its specialized approach to advancing cell therapy capabilities, which plays a critical role in the burgeoning biopharmaceutical sector. This approach not only supports the development of novel treatment methodologies but also helps to set new benchmarks in the industry. By engaging in strategic collaborations and partnerships, Coeptis Therapeutics is able to leverage cutting-edge scientific research and integrate these advances into practical, clinical applications. With its core capabilities focused on the biotechnology space, Coeptis Therapeutics occupies a pivotal position in the driving wave of therapeutic innovations within the pharmaceutical industry, addressing unmet medical needs and contributing significantly to global healthcare advancements.

CEOMr. David Mehalick
SectorHealthcare
IndustryBiotechnology
Employees5

Company Statistics

FY 2024

Profile

$31.56MMarket Cap
$0.00Revenue
0.00Shares Out
5Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-3.22P/E
9.91P/B
N/AEV/Sales
-3.74EV/EBITDA
-4.75P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-161.39%ROA
-490.79%ROE
-155.51%ROIC

Financial Health

$532.88KCash & Cash Equivalents
$4.51MNet Debt
130.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Coeptis Therapeutics Holdings, Inc. (ticker: COEP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 5 employees. Market cap is $32M.

The current price is $16.4 with a P/E ratio of -3.22x and P/B of 9.91x.

ROE is -490.79%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Coeptis Therapeutics Holdings, Inc. (Healthcare) Stock Forecast & Analysis $16.40 | Alpha Lenz